|Bid||88.30 x 1700|
|Ask||90.00 x 5200|
|Day's range||88.98 - 89.72|
|52-week range||69.35 - 89.72|
|PE ratio (TTM)||30.85|
|Earnings date||22 Aug 2017|
|Dividend & yield||1.72 (1.93%)|
|1y target est||91.88|
DUBLIN - June 26, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a new outcomes-based agreement with Aetna (NYSE:AET) for type 1 and type 2 diabetes patients ...
Medtronic Plc said on Monday it signed an agreement with health insurer Aetna Inc under which payment for its insulin pump systems will be tied to how well diabetes patients fare after switching from multiple daily insulin injections. The deal with Aetna will measure health outcomes for patients who transition to one of three Medtronic pumps that self-adjust to keep blood sugar levels in proper range based on patients' individual needs for insulin.
Research Desk Line-up: MGC Diagnostics Post Earnings Coverage LONDON, UK / ACCESSWIRE / June 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Medtronic ...